ANDA 77430, held by Sandoz. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 77430 (Ondansetron Hydrochloride), held by Sandoz, was first approved by FDA on Jun 27, 2007, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 27, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Rx |
| Sep 2, 2016 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 10, 2013 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 27, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters